Moreover, mutations accumulate in SPOP target recognition domains in endometrial and prostate cancers, altering their sensitivity to BET inhibitor therapy (Dai et al., 2017; Janouskova et al., 2017; Zhang et al., 2017). This evidence concerns the gene SPOP and prostate cancer.